Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported a Q4 loss of $(0.81) per share, surpassing the analyst estimate of $(0.91) by 11.09%. This represents a 62.5% improvement compared to losses of $(2.16) per share in the same quarter last year.